Melat Dadigeba; Daniel Yilma; Fassikaw Kebede(2021-05)
Background: Dolutegravir (DTG) is a once-daily unboosted second-generation novel HIV-1 entry and
integrase strand transfer inhibitors with that along with two nucleoside reverse transcriptase inhibitors
(NRTI) preferred ...